Firefly Neuroscience Reports 1,028% Revenue Growth and Improved Net Loss in Latest 10-Q Filing

Firefly Neuroscience, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated revenue of $485,000, a substantial increase from $43,000 in the same period last year, marking a growth of 1,028%. This surge in revenue is primarily attributed to the acquisition of Evoke Neuroscience, which has expanded Firefly's product offerings and customer base. The cost of goods sold for the quarter was $264,000, reflecting the integration of Evoke's material and personnel costs into Firefly's operations.

In terms of operating expenses, Firefly reported a total of $2.23 million for the quarter, up from $2.11 million in the prior year. Research and development expenses rose to $424,000, an increase of 36% compared to $312,000 in the previous year, driven by heightened investment in product development. Conversely, selling and marketing expenses decreased by 32% to $141,000, attributed to a reduction in headcount and consulting costs. General and administrative expenses saw a slight increase of 5%, totaling $1.67 million, primarily due to regular business operating costs.

Firefly's net loss for the quarter was $2.00 million, a significant improvement from a net loss of $12.93 million in the same quarter of 2025. This reduction in loss is largely due to the increased revenue and a decrease in other expenses, including a notable reduction in losses related to the settlement of a convertible promissory note in the previous year. The basic and diluted loss per share improved to $(0.13) from $(1.74) year-over-year, reflecting the company's efforts to enhance its financial performance.

Operationally, Firefly has expanded its reach, with the Evoke System now in use across more than 85 clinical sites in the United States. The company continues to focus on building its customer base and enhancing product adoption rates through its subscription-based model, which aligns revenue growth with clinical utilization. As of March 31, 2026, Firefly had cash and cash equivalents of $3.13 million, an increase from $2.75 million at the end of 2025, bolstered by proceeds from a private placement.

Looking ahead, Firefly anticipates continued negative cash flows as it integrates the Evoke product line and invests in sales expansion. The company has raised a total of $10.25 million through recent financing activities, including a private placement, and is exploring additional capital to support ongoing operations. However, there remains substantial doubt about the company's ability to continue as a going concern, given its accumulated deficit of $113.62 million and ongoing operational losses. Management is focused on disciplined expense management and capitalizing on the synergies from the Evoke acquisition to drive future growth.